IRIS
ARMENI, PATRIZIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 6.390
NA - Nord America 4.503
AS - Asia 2.572
SA - Sud America 272
AF - Africa 35
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 11
Totale 13.796
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.258
IT - Italia 3.019
CN - Cina 934
GB - Regno Unito 836
IE - Irlanda 718
SG - Singapore 627
UA - Ucraina 346
DE - Germania 321
BR - Brasile 232
HK - Hong Kong 209
RU - Federazione Russa 203
CA - Canada 198
SE - Svezia 171
VN - Vietnam 169
TR - Turchia 158
FR - Francia 151
FI - Finlandia 150
KR - Corea 126
NL - Olanda 120
IN - India 94
CZ - Repubblica Ceca 59
BG - Bulgaria 49
PL - Polonia 46
ID - Indonesia 44
IL - Israele 44
ES - Italia 43
BE - Belgio 41
MX - Messico 29
AT - Austria 27
JP - Giappone 25
CH - Svizzera 20
ZA - Sudafrica 16
AE - Emirati Arabi Uniti 15
AR - Argentina 15
IR - Iran 15
IQ - Iraq 13
RO - Romania 13
DK - Danimarca 12
BD - Bangladesh 10
CL - Cile 10
PH - Filippine 9
PK - Pakistan 9
PT - Portogallo 9
AU - Australia 8
EU - Europa 8
TW - Taiwan 8
GR - Grecia 7
MY - Malesia 7
TH - Thailandia 7
UZ - Uzbekistan 7
JO - Giordania 6
LV - Lettonia 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
EC - Ecuador 5
LT - Lituania 5
MA - Marocco 5
NZ - Nuova Zelanda 5
CO - Colombia 4
CR - Costa Rica 4
GE - Georgia 4
KG - Kirghizistan 4
LA - Repubblica Popolare Democratica del Laos 4
PA - Panama 4
SI - Slovenia 4
HN - Honduras 3
NO - Norvegia 3
TN - Tunisia 3
AL - Albania 2
AM - Armenia 2
BY - Bielorussia 2
BZ - Belize 2
EE - Estonia 2
EG - Egitto 2
HU - Ungheria 2
JM - Giamaica 2
KZ - Kazakistan 2
LK - Sri Lanka 2
PE - Perù 2
PS - Palestinian Territory 2
VE - Venezuela 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
BB - Barbados 1
BO - Bolivia 1
BT - Bhutan 1
CG - Congo 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GM - Gambi 1
GT - Guatemala 1
KE - Kenya 1
KH - Cambogia 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 13.790
Salva come PNG Salva come JPEG
Città #
Dublin 717
Milan 642
Southend 532
Chandler 484
Ashburn 463
Dallas 360
Hefei 353
Singapore 332
Jacksonville 276
Rome 260
Ann Arbor 234
Beijing 220
Hong Kong 208
Toronto 148
New York 137
The Dalles 130
Dearborn 128
Los Angeles 128
Seoul 125
Houston 105
Dong Ket 104
Helsinki 91
Wilmington 80
Boston 77
Modena 70
Boardman 64
Lawrence 64
Munich 58
Izmir 56
Naples 56
Bologna 49
Moscow 46
Bari 43
Redwood City 41
Jakarta 39
Redmond 39
Tel Aviv 39
Brussels 38
Florence 38
Turin 38
Seattle 35
São Paulo 35
Warsaw 35
Mountain View 34
Woodbridge 33
Assago 32
Buffalo 32
Frankfurt am Main 32
Casorate Primo 30
Catania 30
London 26
Amsterdam 24
Brooklyn 24
Genoa 24
Ho Chi Minh City 24
Tokyo 24
Montreal 23
Falkenstein 22
Brno 18
Cagliari 18
Chennai 18
Duncan 18
Kunming 18
Nanjing 18
Denver 16
Santa Clara 16
Chicago 15
Johannesburg 15
Pescara 15
Poplar 15
Washington 15
Atlanta 14
Busto Arsizio 14
Hanoi 14
Mexico City 14
Palermo 14
Parma 14
Phoenix 14
Stockholm 14
Brescia 13
Council Bluffs 13
Lappeenranta 13
Palombara Sabina 13
Torino 13
Bonndorf 12
Kocaeli 12
Paris 12
Pisa 12
Verona 12
Ankara 11
Boydton 11
Vienna 11
Fairfield 10
Melendugno 10
Orem 10
Ancona 9
Düsseldorf 9
Fremont 9
Giugliano in Campania 9
Guangzhou 9
Totale 8.191
Salva come PNG Salva come JPEG
Nome #
Digitalizzazione nelle tecnologie per la salute: impatto sui livelli di governo del SSN 601
The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study 412
Prezzi di riferimento per dispositivi medici: criticità, vantaggi e approcci 359
Politiche del farmaco ed impatto sulla spesa: gli effetti di quindici anni di decentramento nel SSN, con un focus sull’adozione di forme alternative di distribuzione dei farmaci 357
La spesa sanitaria: composizione ed evoluzione 316
Dinamiche economiche e performance del settore dei dispositivi medici in Italia 296
PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani 291
I dispositivi medici in Italia: un settore, tanti mercati 281
Report n. 42 OSFAR (Osservatorio Farmaci) 251
La rendicontazione e la remunerazione dei farmaci. Finalità, struttura e gestione del File F in nove Regioni italiane 235
De innovatione: the concept of innovation for medical technologies and its implications for healthcare policy-making 232
Il governo dell'assistenza farmaceutica in Italia: possibili traiettorie di cambiamento 225
L'acquisto di farmaci in Italia: l'effetto di approcci selettivi 219
Cost-minimization analysis to support the HTA of Radiofrequency Echographic Multi Spectrometry (REMS) in the diagnosis of osteoporosis 212
Market access management by pharmaceutical companies in a complex environment: the Italian case study 212
Programma Nazionale di HTA per dispositivi medici: prove tecniche di implementazione 210
A value-based revolution in health care: perspectives, challenges, and emerging approaches to defining and measuring the value of health care technologies 207
Il confronto dei sistemi sanitari in una prospettiva internazionale 206
PHP3 the simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 204
Real-world cost effectiveness of MitraClip combined with medical therapy versus medical therapy alone in patients with moderate or severe mitral regurgitation 202
Il governo regionale dell'assistenza farmaceutica e il suo impatto sulla spesa 201
The future of Funds for Innovative Medicines: results from a Delphi Study 200
Establishing a national HTA program for medical devices in Italy: overhauling a fragmented system to ensure value and equal access to new medical technologies 194
Cost-effectiveness and net monetary benefit of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage III non–small cell lung cancer in the Italian National Health Service 192
Diffusion without evidence: a study on high-risk medical devices 191
Comparative effectiveness of Mitraclip plus medical therapy versus medical therapy alone in high-risk surgical patients: a comprehensive review 187
The impact of HTA and procurement practices on the selection and prices of medical devices 179
L'adozione dell'innovazione tecnologica da parte degli ospedali italiani: un'analisi dei fattori endogeni 175
Programmi di early access dei farmaci e managed entry agreement in Italia: i risultati di un Focus Group (programmi di early access e managed entry agreement) 174
Il confronto dei sistemi sanitari in una prospettiva internazionale 172
Cost-utility analysis of esketamine for patients with treatment resistant depression in Italy 171
La spesa sanitaria: composizione ed evoluzione 170
La spesa sanitaria: composizione ed evoluzione 165
La copertura vaccinale nelle regioni italiane. Un’analisi dell’eterogeneità 160
The impact of generic reference pricing in Italy, a decade on 160
Il confronto dei sistemi sanitari in una prospettiva internazionale 158
The impact of generic reference pricing in Italy, a decade on 155
A meta-analysis of MitraClip combined with medical therapy versus medical therapy alone for treatment of mitral regurgitation in heart failure patients 153
I settori contigui alla sanità: struttura e performance delle imprese farmaceutiche, di dispositivi medici e delle farmacie in Italia 153
When peers count: the effects on integrated type II diabetes care of communication within general practitioner-only subgroups in interprofessional primary care teams 151
L'attività sperimentale sui dispositivi medici 150
Cost-benefit analysis in health care: the case of bariatric surgery compared with diet 149
Digital Twins in healthcare: is it the beginning of a new era of evidence-based medicine? A critical review 147
The invisible costs of obstructive sleep apnea (OSA): systematic review and cost-of-illness analysis 143
Il confronto dei sistemi sanitari in una prospettiva internazionale 143
Implementation of value-based pricing for medicines 143
La spesa sanitaria: composizione ed evoluzione 141
La spesa sanitaria: composizione ed evoluzione 140
The social burden and quality of life of patients with haemophilia in Italy 137
Il confronto dei sistemi sanitari in una prospettiva internazionale 137
Mobile health divide between clinicians and patients in cancer care: results from a cross-sectional international survey 135
Collecting physicians' preferences on medical devices: are we doing it right? Evidence from Italian orthopedists using 2 different stated preference methods 134
Social/economic costs and quality of life in patients with haemophilia in Europe 134
Multi-professional primary care units: what affects the clinical performance of Italian general practitioners? 131
Cost-effectiveness and net monetary benefit of Olaparib maintenance therapy versus no maintenance therapy after first-line platinum-based chemotherapy in newly diagnosed advanced BRCA1/2-mutated ovarian cancer in the Italian National Health Service 131
Il settore dei dispositivi medici in Italia. L’impatto delle politiche pubbliche sulle performance delle imprese 129
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 128
The simultaneous effects of pharmaceutical policies from payers' and patients' perspectives: Italy as a case study 128
Cost-effectiveness of the coronary sinus Reducer and its impact on the healthcare burden of refractory angina patients 125
What type of clinical evidence is needed to assess medical devices? 124
Social/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe 117
Politiche del farmaco: approfondimento sul Value Framework per i farmaci 113
The simultaneous effects of pharmaceutical policies from payers’ and patients’ perspectives: Italy as a case study 112
Social economic costs, health-related quality of life and disability in patients with Cri Du Chat syndrome 112
La spesa sanitaria: composizione ed evoluzione 107
Economic impact of a more extensive use of FENO testing on the Italian population with asthma 103
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis 102
La spesa sanitaria: composizione ed evoluzione 100
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case 99
La spesa sanitaria: composizione ed evoluzione 99
The value of hearing aids for the Italian NHS: a cost-utility analysis 94
Variations in non-prescription drug consumption and expenditure: determinants and policy implications 94
Cost-effectiveness analysis of pressure-controlled intermittent coronary sinus occlusion in elective percutaneous coronary intervention 88
La spesa sanitaria: composizione ed evoluzione 88
La spesa sanitaria: composizione ed evoluzione 88
La spesa sanitaria: composizione ed evoluzione 79
Percutaneous mitral valve repair vs. stand-alone medical therapy in patients with functional mitral regurgitation and heart failure 73
Cost-effectiveness analysis of HRD testing for previously treated patients with advanced ovarian cancer in Italy 72
Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe 71
Use of resource modeling to quantify the organizational impact of subcutaneous formulations for the treatment of oncologic patients: the case of daratumumab in multiple myeloma 62
L’evoluzione del finanziamento dei farmaci in Italia 61
Reflections on the importance of cost of illness analysis in rare diseases: a proposal 61
Elicitation of societal preferences for chronic lymphocytic leukemia’s treatments: a discrete choice experiment 59
Exploring the potential of digital therapeutics: an assessment of progress and promise 57
Health system quality and COVID-19 vaccination: a cross-sectional analysis in 14 countries 53
Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy 52
Individual and team performanc: issues around the role of attributes and relationships among peers 44
The role of health systems in shaping vaccine decisions: Insights from Italy, Mexico, the United Kingdom, and the United States 33
Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes 32
Totale 14.043
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021777 0 0 0 0 0 81 105 60 132 103 108 188
2021/2022935 68 180 36 41 66 12 31 174 41 47 105 134
2022/20232.347 119 127 58 176 153 189 63 101 977 94 165 125
2023/20241.807 104 97 123 89 167 177 105 279 99 136 211 220
2024/20252.490 138 36 170 123 209 157 162 165 571 286 303 170
2025/20262.750 559 647 292 573 605 74 0 0 0 0 0 0
Totale 14.043